

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Vamorolone for treating Duchenne muscular dystrophy [ID4024]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

| |
|---|
| <p>1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?</p> |
| <p>Vamorolone has been studied in clinical trials in boys aged 4 years and older.</p> <p>At consultation it was noted that corticosteroids are not routinely used or recommended in female carriers, even if symptomatic.</p> <p>At the workshop clinicians expressed that they would prescribe vamorolone to girls diagnosed with Duchenne muscular dystrophy unless there were clear reasons not to.</p> <p>Stakeholders also noted concerns about travel distance to receive treatment given the level of disability many patients have.</p> |

| |
|--|
| <p>2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?</p> |
| <p>NICE has kept the remit and population broad so as to be inclusive to all those who are included in the marketing authorisation.</p> <p>If appropriate, the committee may be made aware of issues related to ease of access to treatment for people with Duchenne muscular dystrophy.</p> |

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes were made to the draft scope to highlight potential equality issues.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders related to potential equality issues have been identified.

Approved by Associate Director (name): Ian Watson

Date: 26/07/2023